Evidence mapPaperPMID 39056350Full record

ReviewJournal of the American Heart Association2024

Frailty and Cardiovascular Health.

Kirstyn James, Yasser Jamil, Manish Kumar, Min J Kwak, Michael G Nanna, Saadia Qazi, Aaron L Troy, Jawad H Butt, Abdulla A Damluji, Daniel E Forman and 1 more

Abstract readReview
In one paragraph

Review in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Clinical outcomes after catheter ablation for atrial fibrillation in elderly patients: a meta-analysis with time-to-event data reconstruction.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kirstyn JamesDepartment of Geriatric Medicine Cork University Hospital Cork Ireland.ORCID 0000-0002-0657-5425
Yasser JamilDepartment of Internal Medicine Yale University School of Medicine New Haven CT USA.ORCID 0009-0008-5853-4538
Manish KumarUniversity of Connecticut Hartford CT USA.ORCID 0000-0003-0424-8858
Min J KwakUniversity of Texas Health Science Center at Houston TX USA.ORCID 0000-0003-2778-3984
Michael G NannaDepartment of Internal Medicine Yale University School of Medicine New Haven CT USA.ORCID 0000-0001-5745-1636
Saadia QaziVA Boston Healthcare System Boston MA USA.ORCID 0000-0002-5394-9530
Aaron L TroyDepartment of Medicine Beth Israel Deaconess Medical Center Boston MA USA.ORCID 0000-0001-9844-5718
Jawad H ButtBritish Heart Foundation Cardiovascular Research Centre University of Glasgow UK.ORCID 0000-0002-7380-4144
Abdulla A DamlujiJohns Hopkins University School of Medicine Baltimore MD USA.ORCID 0000-0002-8774-6416
Daniel E FormanDepartment of Medicine (Geriatrics and Cardiology) University of Pittsburgh PA USA.ORCID 0000-0002-5697-2189
Ariela R OrkabyVA Boston Healthcare System Boston MA USA.ORCID 0000-0002-4297-6306

Funding

TREATMENT GOALS FOR PERSONS WITH MULTIFACTORIAL GERIATRIC HEALTH CONDITIONSP30AG021342 · YALE UNIVERSITY · 2002 to 2025
$8.0M
NHLBI NIH HHS K23 HL153771NIA NIH HHS P30 AG021342NIA NIH HHS R03 AG074067
6 · The paper itself

Abstract

The incidence of frailty and cardiovascular disease (CVD) increases as the population ages. There is a bidirectional relationship between frailty and CVD, and both conditions share several risk factors and underlying biological mechanisms. Frailty has been established as an independent prognostic marker in patients with CVD. Moreover, its presence significantly influences both primary and secondary prevention strategies for adults with CVD while also posing a barrier to the inclusion of these patients in pivotal clinical trials and advanced cardiac interventions. This review discusses the current knowledge base on the relationship between frailty and CVD, how managing CVD risk factors can modify frailty, the influence of frailty on CVD management, and future directions for frailty detection and modification in patients with CVD.

Indexed as

Cardiovascular DiseasesFrailtyAgedFrail ElderlyGeriatric AssessmentHeart Disease Risk FactorsHumansIncidencePrognosisRisk AssessmentRisk Factorsagingcardiovascular diseasescardiovascular interventionsfrailtygeriatric syndromesprimary preventionsecondary prevention

Identifiers

PMID39056350
PMCPMC11964060

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.